Previous 10 | Next 10 |
home / stock / biovf / biovf news
The European Medicines Agency's advisory group CHMP has adopted a negative opinion against approval of Swedish Orphan Biovitrum AB's ( OTCPK:BIOVF ) Gamifant (emapalumab) for the treatment of primary hemophagocytic lymphohistiocytosis (HLH) in children under the age of 18. More news on...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2020 Earnings Conference Call July 16, 2020 7:00 AM ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Financial Officer Milan Zdravkovic - Head-Research and Development Conference Call Parti...
The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2020 Q2 earnings Read more ...
Swedish Orphan Biovitrum (STO:SOBI) (OTC: BIOVF ) is a USD 6.2B Swedish biopharmaceutical company engaged in the research, production and distribution of treatments dedicated to rare diseases. In this article, I will provide an in-depth analysis of this company. NB: SOBI has its primary list...
This past Friday, Selecta Biosciences ( SELB ) announced a large deal with Swedish Orphan Biovitrum AB [Sobi] ( OTCPK:BIOVF ) worth a possible $730M plus double-digit royalties, with $100M of that upfront. That's quite a large sum for a company that has a current market cap of $234M. Let's l...
STOCKHOLM , June 14, 2020 /PRNewswire/ -- Sobi™ (STO: SOBI) and Sanofi (EURONEXT: SAN) together with the World Federation of Hemophilia (WFH) and WFH USA , today announced an extension of their support of the WFH Humanitarian Aid Program with an additional donation of up to 500 mi...
Selecta Biosciences (NASDAQ: SELB ) and Swedish Orphan Biovitrum AB ( OTCPK:BIOVF ) have entered into a strategic licensing agreement for the product candidate SEL-212, designed to durably control serum uric acid, reduce immunogenicity, and allow for repeated monthly dosing for t...
STOCKHOLM , May 7, 2020 /PRNewswire/ -- Sobi™ announced today that the results from the pivotal phase 2/3 study evaluating the efficacy and safety of emapalumab in patients with primary haemophagocytic lymphohistiocytosis (HLH) were published in the New England Journal of ...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q1 2020 Earnings Conference Call April 29, 2020 07:00 AM ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Financial Officer Milan Zdravkovic - Head-Research and Development Conference Call Parti...
The China National Medical Products Administration has approved Dova Pharmaceuticals' Doptelet (avatrombopag) for chronic liver disease patients with thrombocytopenia (low blood platelets) who are undergoing a procedure. More news on: Swedish Orphan Biovitrum AB (publ), Healthcare stocks...
News, Short Squeeze, Breakout and More Instantly...
Swedish Orphan Biovit Ord Company Name:
BIOVF Stock Symbol:
OTCMKTS Market:
WALTHAM, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi ® ), today announced the presentation of three abstracts that highlights data from its myelofibrosis treatment option at the American Society of Clin...
WALTHAM, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi ® ), today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to emapalumab-lzsg being investigated as a pot...
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...